The payer backlash against PTC’s deflazacort for Duchenne MD begins with some damning comparison shopping
PTC Therapeutics has a few weeks to go before it wraps its $190 million deal to buy the controversial drug deflazacort from Marathon Pharmaceuticals and starts marketing the old steroid with a new FDA approval for Duchenne muscular dystrophy. But even before the biotech decides its price, the payer kickback against this drug has already begun.
Unless it’s virtually free, it’s clear that for now some don’t want to pay for it.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
